What the studies show
SCALE Kids, 82 children, 56 weeks: BMI −5.8% versus +1.6% on placebo. One small trial; not yet a licensed indication in most jurisdictions.
Human trials exist and mostly agree, but there are too few of them, they are too small, or one big one is still reading out. Expect the grade to move.
- 1Fox CK, et al. Liraglutide for children 6 to <12 years of age with obesity (SCALE Kids).N Engl J Med, 2024; DOI 10.1056/NEJMoa240737982 children, 56 weeks.
In context
Liraglutide is a once-daily GLP-1 receptor agonist and the drug that proved the class. In the 3,731-person SCALE trial it produced 8.0% weight loss at 56 weeks against 2.6% on placebo, and in the 9,340-person LEADER trial it cut major cardiovascular events by 13% and cardiovascular death by 22% in people with type 2 diabetes. It is approved almost everywhere, now generic, and less effective than the weekly drugs that followed it.
Liraglutide is approved (saxenda, victoza). Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Liraglutide proven to help with body weight?
What studies are behind the grade?
Is Liraglutide approved for this?
Other outcomes for Liraglutide
- ABody weight (adults)5 SCALE RCTs
- AMajor cardiovascular events1 large outcome RCT
- ABlood glucose (HbA1c)LEAD programme, 6 RCTs
- ABody weight (adolescents 12–17)1 RCT
- AGI side effectsadverseAll trials
- AGallbladder eventsadverseSCALE + LEADER
Reviewed 3 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →